Abstract
We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on the fatality and the requirement of mechanical ventilation for the treatment of moderate to severe COVID-19 patients. We searched available literature and reported it by using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Until June 1, 2021, we searched PubMed, bioRxiv, medRxiv, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar by using the keywords “Favipiravir” and terms synonymous with COVID-19. Studies for Favipiravir treatment compared to standard of care among moderate and severe COVID-19 patients were included. Risk of bias assessment was performed using Revised Cochrane risk of bias tool for randomized trials (RoB 2) and ROBINS-I assessment tool for non-randomized studies. We defined the outcome measures as fatality and requirement for mechanical ventilation. A total of 2702 studies were identified and 12 clinical trials with 1636 patients were analyzed. Nine out of 12 studies were randomized controlled trials. Among the randomized studies, one study has low risk of bias, six studies have moderate risk of bias, and 2 studies have high risk of bias. Observational studies were identified as having moderate risk of bias and non-randomized study was found to have serious risk of bias. Our meta-analysis did not reveal any significant difference between the intervention and the comparator on fatality rate (OR 1.11, 95% CI 0.64-1.94) and mechanical ventilation requirement (OR 0.50, 95% CI 0.13-1.95). There is no significant difference in fatality rate and mechanical ventilation requirement between Favipiravir treatment and the standard of care in moderate and severe COVID-19 patients.
Keywords: COVID-19; Effectiveness; Favipiravir; Meta-analysis; Systematic review.
【저자키워드】 COVID-19, Meta-analysis, Favipiravir, systematic review, Effectiveness, 【초록키워드】 Treatment, Meta-analysis, review, clinical trial, Randomized controlled trials, mechanical ventilation, randomized trial, Favipiravir, systematic review, Intervention, observational studies, observational study, controlled trials, Risk of bias, Patient, Reporting, moderate, outcome measures, fatality, meta-analyses, systematic reviews, high risk, Google Scholar, moderate to severe, assessment tool, Standard of care, randomized trials, PRISMA, significant difference, 95% CI, no significant difference, item, severe COVID-19 patients, outcome measure, Fatality rate, ClinicalTrials, medRxiv, comparator, bioRxiv, CENTRAL, non-randomized studies, synonymous, randomized studies, defined, analyzed, performed, reported, was performed, searched, non-randomized, Controlled, risk of bia, RoB 2, severe COVID-19 patient, with COVID-19, 【제목키워드】 Favipiravir,